Top 10 urologic imaging stories in 2024

There has been a lot of news about imaging technologies in urology over the past year. To celebrate these breakthroughs, the editorial staff at Urology Times® are showcasing our best content on urologic imaging from 2024.

Dr. Reiter discusses the efficacy of PSMA-PET scans

Prostate-specific membrane antigen (PSMA)-PET imaging has proven to be disruptive technology in the detection of prostate cancer. In this interview, Robert Reiter, MD, MBA, discusses the accuracy of PSMA-PET scans, false negative and false positive rates, and how treatment with androgen deprivation therapy affects PSMA uptake. Read the full interview here

PSMA-PET leads imaging breakthroughs in prostate cancer paradigm

In this interview, Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging. He also touches on the importance of implementing a multidisciplinary approach when using these next-generation imaging agents in clinical practice. Read the full interview here

Expert discusses use of prostate MRI with and without contrast

In this video, Leonardo Kayat Bittencourt, MD, PhD, discusses mpMRI of the prostate. Watch the video here

Harnessing the full power of PSMA-PET requires multi-disciplinary approach

PSMA-PET imaging has successfully disrupted the prostate cancer paradigm and experts agree that unleashing the full potential of this breakthrough requires a multidisciplinary approach. Read more here

Actinium-225-PSMA therapy shows strong antitumor activity in mCRPC

Actinium-225 PSMA radioligand therapy demonstrated strong antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, including individuals who had received ¹⁷⁷Lu-PSMA RLT, according to findings from a retrospective study published in The Lancet. Read more here

Expanded label sought for 177Lu-PSMA-617 in prostate cancer

Novartis announced plans to file for an expanded label of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) to include patients with metastatic castration-resistant prostate cancer (mCRPC) in the pre-taxane-based chemotherapy setting following additional positive data from the phase 3 PSMAfore study (NCT04689828). Learn more here

FDA clears IND for 225Ac-J591 in advanced prostate cancer

The FDA has granted clearance to an investigational new drug (IND) application for 225Ac-J591 (CONV01-α), a prostate-specific membrane antigen-targeted monoclonal antibody under investigation for the treatment of patients with advanced prostate cancer, announced Convergent Therapeutics, the developer of the therapy, in a news release. Read more here

Dr. Spratt on the importance of a multidisciplinary approach to PSMA-PET

In this video, Daniel Spratt, MD, discusses the critical need for a multidisciplinary approach to PSMA-PET in order to harness the full potential of the breakthrough. Watch the video here

Study compares single photon emission CT with 18F-PSMA-PET/CT in prostate cancer

Although single photon emission computer tomography (SPECT/CT) with ⁹⁹mTc‐PSMA-SPECT/CT had a slightly lower rate of lesion detection versus 18F-PSMA-PET/CT, this difference had no impact on clinical staging, suggesting the cost-effective modality may be a viable alternative for the primary diagnosis of prostate cancer in areas with limited income and access. The findings came from a small, prospective study presented in a poster session at the 2024 ASCO Genitourinary Cancers Symposium.Read more here

European market for piflufolastat F 18 continues to expand

The European roll-out of piflufolastat (¹⁸F) (Pylclari; (18F)-DCFPyL) continues to progress with the first commercial doses of the diagnostic administered in both Austria and France for the detection of prostate-specific membrane antigen-positive lesions with PET in patients with prostate cancer, according to separate news releases from Curium, the developer of the agent. Learn more here